KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $102.7 million.

  • Novavax's Treasury Shares rose 822.58% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 822.58%. This contributed to the annual value of $95.9 million for FY2024, which is 388.76% up from last year.
  • Novavax's Treasury Shares amounted to $2.3 million in Q3 2025, which was up 6644.42% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Treasury Shares ranged from a high of $2.3 million in Q3 2025 and a low of $408989.0 during Q1 2021
  • Its 5-year average for Treasury Shares is $1.1 million, with a median of $875371.0 in 2023.
  • Its Treasury Shares has fluctuated over the past 5 years, first surged by 168942.38% in 2021, then soared by 177.37% in 2023.
  • Quarter analysis of 5 years shows Novavax's Treasury Shares stood at $85.1 million in 2021, then increased by 6.53% to $90.7 million in 2022, then grew by 1.77% to $92.3 million in 2023, then grew by 3.89% to $95.9 million in 2024, then grew by 7.1% to $102.7 million in 2025.
  • Its Treasury Shares was $102.7 million in Q3 2025, compared to $102.5 million in Q2 2025 and $101.9 million in Q1 2025.